Our laboratory has delineated that the phosphatidylinositol 3 0 kinase (PI3K)/AKT/IjB kinase (IKK) pathway positively regulates NFjB and b-catenin, both important transcriptional regulators in colorectal cancer (CRC). Therefore, we investigated the effect of inhibiting the PI3K/AKT/IKKa pathway in regulating the inappropriate constitutive activation of NFjB and b-catenin in CRC cell lines. SW480 and RKO CRC cell lines demonstrate constitutive activation of AKT as well as both NFjB-and b-catenin-dependent transcription. The constitutive activation of NFjB-and b-catenin-dependent transcription is inhibited by transiently transfecting either kinase dead (KD) IKKa, which blocks IKKa kinase activity, KD AKT, which blocks AKT activity, or wildtype (WT) PTEN, which inhibits PI3K and AKT activity. The ability of KD IKKa, KD AKT or WT PTEN to decrease b-catenindependent transcription is independent of their effects on NFjB. Inducible expression of either KD IKKa or WT PTEN strongly inhibits both the constitutive NFjB-and b-catenin-dependent promoter and endogenous gene activation. Targeted array-based gene expression analysis of this inducible system reveals that many of the genes downregulated upon inhibition of this pathway are involved in tumor angiogenesis and metastasis. The activation of this pathway and the expression of the three most repressed genes was further analysed in samples of CRC. These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis.
Introduction
The transcription factor NFkB is constitutively activated in many types of cancers. NFkB regulates the expression of several antiapoptotic genes and is required to overcome cell death induced by tumor necrosis factor (TNF), chemotherapy and irradiation Haefner, 2002; Orlowski and Baldwin Jr, 2002; Lin and Karin, 2003) . There is growing evidence that loss of the normal regulation of the IKK/NFkB pathway is a major factor contributing to the deregulated growth, resistance to apoptosis and propensity to metastasize observed of many cancers (Rayet and Gelinas, 1999; Bharti and Aggarwal, 2002; Gilmore et al., 2002; Orlowski and Baldwin Jr, 2002; Gilmore, 2003; Lin and Karin, 2003) . Many CRC cell lines and tissues show constitutive IKK/NFkB activity, and maintenance of this activity is necessary for CRC cell proliferation and resistance to apoptosis (Bours et al., 1994; Lind et al., 2001) . The IKK complex, responsible for the cytokineinduced activation of latent NFkB (Baeuerle and Henkel, 1994; Siebenlist et al., 1994; Verma et al., 1995; Thanos and Maniatis 1995; Rothwarf and Karin, 1999) , consists of the two highly related kinase subunits IKKa and IKKb, as well as a third structural subunit, IKKg (Rothwarf and Karin, 1999) . All the three subunits are necessary for NFkB-dependent gene expression (Li et al., 2002; Sizemore et al., 2002) . It was first thought that the only substrates of IKK were the cytoplasmic inhibitors of NFkB (IkBs). However, our recent work and those of others have revealed that the IKK complex has additional targets whose phosphorylation is necessary for NFkB-stimulated gene expression. Both IKKb and IKKg are required for cytokineinduced degradation of IkB (Li Q et al., 1999 (Li Q et al., , 2000 Li ZW et al., 1999; Tanaka et al., 1999; Makris et al., 2000; Rudolph et al., 2000; Schmidt-Supprian et al., 2000) . In addition, both IKKa and IKKb are required to phosphorylate and stimulate the transactivation function of p65/RelA subunit of NFkB (Sakurai et al., 1999 (Sakurai et al., , 2003 Madrid et al., 2000 Madrid et al., , 2001 Ashikawa et al., 2002; Sizemore et al., 2002; Yang et al., 2003) , as well as for the processing of p105 and p100 to the p50 and p52 subunits of NFkB, respectively (Heissmeyer et al., 1999) . IKKa is also involved in the phosphorylation of Histone H3 on NFkB-dependent promoters (Anest et al., 2003; Yamamoto et al., 2003) . Therefore, the IKK complex phosphorylates several novel target proteins in the process of activating NFkB-dependent genes.
Our data presented here and those of others also indicate that IKKa can positively regulate b-catenin, another transcription factor important in CRC (Lamberti et al., 2001; Albanese et al., 2003) . b-Catenin is a transcriptional regulator which, when bound to T-cell factor (TCF) and lymphoid-enhancer factor (LEF), provides a potent transcriptional transactivation domain (Polakis, 2000) . b-Catenin plays a crucial role in the Wingless/Wnt signaling pathway. b-Catenin is involved in cell-cell adhesion through its binding to the cytoplasmic domain of E-cadherin (Polakis, 2000) . The protein product of the adenomatous polyposis coli (APC) tumor suppressor gene competes with E-cadherin for binding to b-catenin. In normal cells, both components of the APC/b-catenin complex are phosphorylated by the serine-threonine kinase glycogen synthase kinase 3b (GSK3b), which results in b-catenin being effectively degraded by the ubiquitin-mediated proteosome pathway, keeping free cytosolic b-catenin levels low. When the Wnt signaling pathway is activated, GSK3b-dependent phosphorylation of the APC/b-catenin complex is inhibited and cytosolic b-catenin accumulates. Accumulated b-catenin can then bind to the cytosolic TCF/LEF proteins and the resulting complex enters the nucleus to activate transcription. The APC protein, mutated in the hereditary colorectal cancer syndrome familial adenomatous polyposis (FAP) and also in a large proportion of sporadic colorectal cancers, is usually truncated and is thus unable to form a complex with b-catenin and as a result b-catenin is not available for degradation (Polakis, 2000) . Deregulation of this pathway leads to transcriptionally active b-catenin-Tcf/Lef complexes, which then activate a variety of oncogenic target genes Tetsu and McCormick, 1999; Polakis, 2000) . The overwhelming genetic evidence of the derangement of the b-catenin signaling pathway in CRC strongly suggests a role for the b-catenin pathway in tumor development Polakis, 2000) .
Together, these results underscore an important role for the activation of both the b-catenin and NFkB pathways in CRC development and in progression to invasion and metastasis. We have previously demonstrated a role of the PI3K/AKT cell survival pathway and the PTEN tumor suppressor pathway in the positive and negative regulation, respectively, of the antiapoptotic transcription factor NFkB (Sizemore et al., 1999 (Sizemore et al., , 2002 . AKT is a serine/threonine kinase activated by phosphorylation and lipid binding stimulated by the PI3K signaling pathway (Burgering and Coffer, 1995) . The PTEN lipid phosphatase acts as a tumor suppressor by negatively regulating PI3K/AKT-driven cell growth and survival (Stambolic et al., 1998) . One of the mechanisms associated with the ability of AKT to prevent apoptosis is its role in activating NFkB. AKT stimulates IKK to phosphorylate and activate the p65 subunit of NFkB (Sakurai et al., 1999; Sizemore et al., 1999 Sizemore et al., , 2002 Madrid et al., 2000 Madrid et al., , 2001 Haller et al., 2002) . Our data presented here and those of other laboratories (Lamberti et al., 2001; Albanese et al., 2003) also indicate that the PI3K/AKT/IKKa pathway can positively regulate b-catenin-dependent transcription. Therefore, we investigated the effect of inhibiting the PI3K/AKT/ IKKa pathway in regulating the inappropriate constitutive transcriptional activation of both NFkB and bcatenin in CRC cell lines and the expression of genes regulated by this pathway in human CRC.
Results

AKT is constitutively activated in some CRC cell lines
To determine whether AKT is activated in CRC cells, five different tumorigenic CRC cancer cell lines were evaluated. Cells were grown in serum-free medium and treated overnight with the PIK3 inhibitor, LY 294 002 (LY). Levels of activated AKT were analysed by Western blot analysis using a phospho-specific antibody for AKT phosphorylated at serine 473 ( Figure 1a ). Both SW480 and RKO cells contain high constitutive levels of phosphorylated AKT, which is dramatically inhibited by 20 mM LY. To ensure that the phosphorylated AKT observed in the SW480 and RKO cells is enzymatically active, an in vitro kinase assay using an AKT substrate peptide was performed in untreated and LY-treated HT29, SW480, and RKO cells. Both SW480 and RKO cells have 4-8-fold higher levels of AKT activity compared to HT29 cells and treatment with LY significantly inhibits AKT activity (Figure 1b b-catenin-dependent transcriptional activity in a PI3K/ AKT-dependent manner. Therefore, we investigated the role of the PI3K/AKT/IKKa pathway in the activation of NFkB and b-catenin in CRC cell lines. In both the SW480 and RKO CRC cell lines that have elevated AKT activity, NFkB-and b-catenin-dependent transcription was constitutively activated in a PI3K/AKTdependent manner (Figure 2) . Addition of the PI3K inhibitor, LY, resulted in a dose-dependent reduction in both NFkB-dependent ( Figure 2a ) and b-catenindependent ( Figure 2b ) promoter activity in both CRC cell lines. As published previously by our group (Sizemore et al., 1999 (Sizemore et al., , 2002 , neither IkBa phosphorylation ( Figure 2c (Figure 3 ). The ability of WT PTEN to inhibit both NFkB and b-catenin activation in these cells is dependent on its lipid phosphatase activity as the C124A PTEN mutant had no effect on either promoter construct (Figure 3a and b) . Additionally, KD AKT also inhibited the constitutive NFkB and b-catenin activation, indicating that the inhibition by WT PTEN was due to its effect on AKT and not other PI3K-dependent pathways (Figure 3a and Other genes likely to be important in CRC, including Several genes encoding proteins implicated in angiogenesis and metastasis showed a consistent and significant reduction in mRNA expression, following induction of either KD IKKa or WT PTEN in the RKO cell lines (Table 1) . Those genes included IL-8, uPA, vascular endothelial growth factor-C (VEGF-C), vascular endothelial growth factor (VEGF), vascular endothelial growth factor-B (VEGF-B), COX2, EGF, transforming growth factor-a (TFGa), osteopontin, MMP2 and MMP9. The fold decreases in the expression of the genes ranged from 14.2 to 2.7 (Table 1 ). The regulation of IL-8, EGF, uPA, COX2, MMP9 (Figure 4c ), as well as the other genes (data not shown) in KDA and WPT RKO cells was confirmed by Northern blot analysis and semiquantitative real-time PCR. To determine whether the genes identified were dependent on either NFkB or b-catenin, or both, RKO cells stably overexpressing either the IkBa SR or WT APC, to inhibit only NFkB or b-catenin, respectively, were also screened by the gene arrays. IL-8, uPA, VEGF-C, VEGF, VEGF-B, COX2, and osteopontin are dependent on both NFkB and bcatenin, while EGF, TGFa, MMP2 and MMP9 are dependent on NFkB alone (Table 1) . In contrast to HT29 cells, which do not demonstrate constitutive activation of the AKT/IKK/NFkB and b-catenin pathway, both SW480 and RKO cells expressed high constitutive levels of both IL-8 and uPA, which were significantly reduced by inhibition of PI3K/AKT and stimulated by TNF treatment (Figure 5a ). Additionally, conditioned medium from the SW480 and RKO cells contained elevated constitutive levels of IL-8 and uPA that was regulated in a PI3K/AKT-dependent manner and further upregulated by TNF treatment (Figure 5b ). HT29 cells did not demonstrate any detectable constitutive levels of either IL-8 or uPA, but both proteins were inducible by TNF in these cells (data not shown).
The AKT/IKK/NFkB and b-catenin pathway and angiogenic/metastatic gene expression is upregulated in human CRC
We first screened for activation of this pathway by western blot analysis of five CRCs and matched normal colon mucosa. In contrast to their matched normal tissue, most of the CRCs demonstrated constitutively activated and phosphorylated AKT, IKK, and p65 NFkB, as well as elevated levels of b-catenin and the NFkB-and b-catenin-dependent target IL-8 ( Figure 6 ). We next investigated three of the identified NFkB-and b-catenin-dependent genes whose expression was most significantly reduced by inactivation of the AKT/IKKa pathway in the RKO CRC cell line. We analysed IL-8, uPA, and VEGF-C expression using a cancer profiling array containing normalized cDNAs from tumor and corresponding normal tissues. Elevated expression of IL-8, uPA, and VEGF-C mRNAs was observed in tumors of the colon and rectum compared to matched (Figure 7) . A greater than twofold increase in expression of IL-8 was observed in about 85% of colon and 78% of rectal tumors, for uPA in about 75% of colon and 79% of rectal tumors, and for 
Discussion
Our results underscore for the first time an important role for the PI3K/AKT/IKK pathway in the activation of both the NFkB and b-catenin transcription factors in the regulation of an aberrant genetic program in colorectal cancer development. Aberrant activation of PI3K and AKT is observed in many human malignancies. However, which of the signal transduction pathways are altered by aberrant PI3K/AKT in tumors has not been fully explored. In the present study, we show not only that the PI3K/AKT/IKKa pathway regulates both NFkB-and b-catenin-dependent transcription in CRC cells, but also that this pathway regulates genes implicated in both angiogenesis and metastasis, potentially playing a key role in colorectal cancer progression. Using MEFs lacking both IKKa and IKKb, we found that restoration of a kinase-active IKKa, but not IKKb, positively regulates b-catenin-dependent transcription and is reliant on the activity of PI3 K and AKT (data not shown). Two previously published studies also showed that IKKa can positively regulate b-catenindependent transcription (Lamberti et al., 2001; Albanese et al., 2003) . One of these studies also supports our finding that IKKa-driven activation of b-catenin-dependent transcription relies on the activity of PI3K and AKT (Albanese et al., 2003) . We are currently investigating the potential mechanisms of the AKT/IKKamediated activation of b-catenin-dependent signaling and transcription.
As for the role that this pathway plays in CRC, five different CRC cell lines were tested. Two of the CRC cell lines, SW480 and RKO, demonstrated a high level of constitutive AKT phosphorylation and activation. They also showed high basal constitutive activation of both NFkB-and b-catenin-dependent transcriptional activity, which was inhibited by both pharmacologic and genetic inhibition of PI3K and AKT activity, as well as by overexpression of KD IKKa but not KD IKKb. Our data demonstrating that KD IKKa, but not KD IKKb, blocks b-catenin-dependent promoter activity in the RKO CRC cell line (Figure 3d) indicates that IKKa plays the same unique role of regulating b-catenin activity as it does in MEFs (data not shown, Lamberti et al., 2001; Albanese et al., 2003) ). Previously, we and others have demonstrated that overexpression of PTEN, KD AKT and KD IKKa negatively regulates NFkBdependent transcription (Gustin et al., 2001; Koul et al., 2001; Pianetti et al., 2001; Mayo et al., 2002; Sizemore et al., 2002) . In this study, we demonstrate that the PI3K/AKT/IKKa pathway also regulates b-catenindependent transcription. Importantly, we also demonstrate using the IkBaSR and KD IKKb that the inhibition of b-catenin-dependent transcription mediated by transient overexpression of either PTEN, KD AKT, or KD IKKa in the RKO cells is independent of their ability to regulate NFkB activity. Others have previously shown that the b-catenin/TCF/LEF site on the cyclin D promoter is inhibited by overexpression of the IkBaSR in DU145 prostate cancer cells (Albanese et al., 2003) . This result disagrees with our results that regulation of b-catenin by this pathway is independent of its effects on NFkB (Figure 3) . This difference could possibly be explained by how b-catenin transcription is being driven in this study. In Albanese et al., the authors drive b-catenin-dependent transcription by transient overexpression of a constitutively activated form of the p110 subunit of PI3K. In our study, the basal constitutive activation of b-catenin is being inhibited in CRC cells.
Using an inducible model system to express either PTEN or KD IKKa in RKO cells, we also identified genes implicated in angiogenesis and metastasis that are regulated by this pathway (Table 1) , many of which are dependent on both NFkB-and b-catenin-dependent transcription. IL-8, a CXC chemokine, is highly upregulated in a variety of cancers including colorectal cancer (Ueda et al., 1994; Wigmore et al., 2001; Haraguchi et al., 2002) . IL-8 can induce cell mitogenesis, migration and angiogenesis (Shi et al., 2001) , and has been shown to induce endothelial cell chemotaxis, migration, and neovascularization (Koch et al., 1992; Levy et al., 2002) . uPA is a serine protease that converts inactive plasminogen into plasmin and is therefore essential in the initiation of the cascade of proteolytic steps necessary to degrade extracellular matrix allowing for migration and invasion (Blasi and Carmeliet, 2002) . VEGF-C, a member of the VEGF superfamily, is a mitogen for both vascular and lymphatic endothelial cells (Clauss and Schaper, 2000) , which plays an important role in invasion in CRC cancer (Furudoi et al., 2002) . Elevated expression of VEGF, VEGF-B, and VEGF-C correlates with CRC progression and invasion (Hanrahan et al., 2003) . In addition to our studies, the known NFkB targets IL-8, uPA, and VEGF have been recently shown to be transcriptional targets of b-catenin (Levy et al., 2002; Easwaran et al., 2003; Hiendlmeyer et al., 2004 ). We also demonstrate that NFkB and/or b-catenin are involved in the regulation of the other genes identified in our CRC cell line model. COX2 is involved in CRC progression and is a major therapeutic target in the treatment of CRC and other cancers (Gupta and Dubois, 2001 ). EGF and TGFa are autocrine growth factors that bind the epidermal growth factor receptor (EGFR). These growth factors and the EGFR are widely expressed in advanced CRCs and other types of tumors. Currently, clinical trials blocking this pathway with anti-EGFR monoclonal antibodies (cetuximab and ABX-EGF) and inhibiting its intrinsic tyrosine kinase with small molecules (gefitinib [Iressa] and erlotinib Tarceva] ) are currently ongoing for CRC cancer (Cohen, 2003) . SPP1 or osteopontin, a secreted integrin-binding protein, has recently been identified as a lead marker for CRC cancer progression using pooled tumor sample expression profiling (Agrawal et al., 2003) . The MMPs, including MMP2 and MMP9, are a group of zinc-dependent endopeptidases implicated in the degradation of extracellular matrix (ECM) during the metastatic process. Considerable evidence in preclinical models demonstrate that MMP inhibitors (MMPIs) are effective at multiple stages of CRC tumor progression, such as reducing the number of adenomas, inhibiting the growth and establishment of primary CRC tumors, and reducing metastasis to the lung and liver (Wagenaar-Miller et al., 2004; Zucker and Vacirca, 2004) . Our demonstration that this pathway and three of the most repressed identified genes are highly upregulated in actual human patient CRC samples (Figures 6 and 7) supports the strength of our in vitro model system for the discovery and identification of potential therapeutic targets and diagnostic markers for the treatment of CRC. Interestingly, two (IL-8 and VEGF-C) of the three genes identified by our model system that were screened by the cancer profiling arrays (Figure 7 ) demonstrated highly specific upregulation only in GI and CRC cancers as compared to other malignancies (data not shown). Upregulation of IL-8 was highly specific for tumors of the stomach, colon, and rectum as compared to other tumors, while uPA generally showed higher expression in all tumors compared to normal tissues except for the kidney, and VEGF-C expression generally demonstrated higher expression in tumors of the stomach, colon, and rectum only (data now shown). We are currently investigating the expression of the other identified repressed genes in human CRC, the consequence of repressing this pathway on global gene expression, and how modulation of this pathway and its genes affects CRC cell invasion, metastasis, and angiogenic potential both in vitro and in vivo.
In conclusion, our studies provide key insight into how aberrant activation of the AKT/IKKa signaling pathway can regulate and integrate both NFkB and bcatenin to facilitate tumor progression by controlling the transcription of genes implicated in tumor angiogenesis and metastasis. Our hypothesis is that, in addition to tumor initiation by APC mutations that increase the stability of b-catenin, the AKT/IKKa pathway may later become activated, stimulating not only activation of NFkB but also further deregulating b-catenindependent signaling and transcription during CRC progression (Figure 8 ). This further deregulation of bcatenin-dependent signaling by the AKT/IKKa pathway supports a role for b-catenin much later in CRC progression, and together with the consequent NFkB activation provides new insight into the pathways promoting CRC tumor angiogenesis and metastasis.
Materials and methods
Biological reagents and cell culture
Recombinant human TNF is from Preprotech (Rocky Hill, NJ, USA). The PI3K inhibitor LY is from Sigma (St Louis, MO, USA). The zeocin, hygromycin, and PN are from Invitrogen (Carlsbad, CA, USA). Polyclonal anti-b-actin, anti-Flag, anti-green fluorescent protein (GFP), anti-uPA, anti-PAI-1, anti-IKKa/b, and anti-b-catenin are from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to Akt, Akt phosphorylated at serine 473, IkBa, IkBa phosphorylated at serines 32 þ 36, p65 NFkB, p65 NFkB phosphorylated at serine 536, and IKKa and b phosphorylated at serines 180 and 181, respectively, are from Cell Signaling Technology, Inc. (Beverly, MA, USA). Polyclonal anti-IL-8 is from R&D Systems (Minneapolis, MN, USA). The RKO, SW480, HT29, HCT116, and DLD-1 CRC cell lines were obtained from ATCC (Manassas, VA, USA). RKO cells stably expressing IkBa super repressor were generated by transfection and selection with G418 for the pLXIN retroviral vector plasmid from Clontech (Palo Alto, CA, USA), which is engineered to express a mutant IkBa containing serine-toalanine substitutions at positions 32 and 36. RKO cells stably overexpressing WT APC were generated by transfection and selection with G418 for the pCMVNeo-APC plasmid provided by Bert Vogelstein and Kenneth W Kinzler at the Johns Hopkins University Medical Institution (Baltimore, MD, USA). All cells were maintained in Dulbecco's modified Eagle medium, supplemented with 10% fetal calf serum, 100 mg/ml penicillin G, and 100 mg/ml streptomycin. For all experiments, unless otherwise indicated, cells at 80% confluence on 100-mm dishes were either treated with LY (indicated concentrations) and/or stimulated with TNF (25 ng/ ml) at 371C for the indicated times. All results are typical of at least three independent experiments.
Transfection and reporter assays
The NFkB-dependent reporter plasmid p5XIP10kB, provided by Bryan Williams at the Cleveland Clinic Foundation . KD IKKa and IKKb were provided by David Donner (Ozes et al., 1999) . The KD AKT (AKTK179A) was provided by Julian Downward (Burgering and Coffer, 1995) . WT PTEN and the lipid phosphatase mutant C124A PTEN were provided by Kenneth Yamada (Tamura et al., 1998) . CRC cells were transfected co-transiently by using Fugene with 2 mg of p5XIP10kB or pOT with 0.5 mg of pSV2-bgal, and where indicated increasing concentrations of vector, KD IKKa, KD IKKb, KD AKT, WT PTEN, C124A PTEN, or IkBaSR. Luciferase or galactosidase activity was determined with the luciferase assay system or chemiluminescent reagents from Promega (Madison, WI, USA) 36 h following transfection.
Where indicated, cells were treated for 24 h with LY or PN. Luciferase activity was normalized to b-galactosidase activity to control for transfection efficiency.
Short interfering RNA
The mammalian expression vector, pSUPER from OligoEngine (Seattle, WA, USA) was used for expression of siRNA for IKKa and AKT. The gene-specific inserts include the19-nucleotide sequence corresponding to nucleotides 1409-1427 downstream of the transcription start site (agaagactatagcaggctc) of IKKa or the 19-nucleotide sequence corresponding to nucleotides 1943-1961 downstream of the transcription start site (gctgctgggcaaaggcact) of AKT, which are separated by a nine-nucleotide noncomplementary spacer (tctcttgaa) from the reverse complement of the same 19-nucleotide sequence. These vectors were referred to as pSUPER-IKK1 and pSUPER-AKT, respectively. A control vector (pSUPERControl) was constructed using a 19-nucleotide sequence (gcgcgctttgtaggattcg) with no significant homology to any mammalian gene sequence and therefore serves as a nonsilencing control was from OligoEngine. These sequences were inserted into the pSUPER backbone after digestion with BglII and HindIII, and transformed into BL21-A1 One Shott supercompetent cells from Invitrogen according to the manufacturer's instructions. Several clones were obtained, and the vectors were amplified. The insertion of the IKKa or AKT sequence into the pSUPER backbone was verified by sequencing. CRC cells were transfected co-transiently by using Fugene with 2 mg of p5XIP10kB or pOT with 0.5 mg of pSV2-bgal, and where indicated increasing concentrations of pSUPER-Control, pSUPER-IKK1, or pSUPER-AKT. Luciferase or galactosidase activity was determined as above.
Western analysis
Cells, untreated or treated with LY or TNF, were washed once with phosphate-buffered saline and lysed for 30 min at 41C in 1 ml of 0.5%. Nonidet P-40 lysis buffer, as described previously (Welch and Wang, 1993) . For analysis of conditioned medium, cells at approximately 90% confluence were incubated overnight in serum-free medium. The conditioned medium was then concentrated 50 times using Amicon Ultra filters from Millipore (Billerica, MA, USA). For analysis of human tumors, samples of normal and colorectal tumor tissue were obtained using protocols approved by the Cleveland Clinic Foundation Institutional Review Board. The samples were snap frozen and stored at À801C. Cryostat sections (10 mm) were extracted in the Nonidet P-40 lysis buffer as described above. Equal amounts of cell, medium, or tissue extracts were fractionated by SDS-PAGE and transferred to nitrocellulose membranes. Analysis was performed with the indicated primary antibodies, which were visualized with horseradish peroxidase-coupled goat anti-rabbit or -mouse immunoglobulins, using the ECL Western blotting detection system from Perkin-Elmer Life Sciences (Boston, MA, USA).
Immunoprecipitation and AKT kinase assay
The cells were untreated or treated with LY for 24 h. Cells were washed once with phosphate-buffered saline and lysed as for Western analysis. Cellular debris was removed by centrifugation at 16 000 Â g for 15 min. For immunoprecipitations, cell extracts were incubated with 3 mg of total AKT antibody for 4 h, followed by incubation for 1 h with 50 ml of protein ASepharose beads (50% suspension). In vitro phosphorylation was performed as per manufacturer's instructions using B1 mg of the AKT substrate peptide from Upstate (Lake Placid, NY, USA) with the immunoprecipitated AKT as the kinase at 301C for 30 min. Following the kinase reaction, phosphorylation of the AKT substrate was analysed by SDS-PAGE, followed by autoradiography.
Gel Electrophoretic mobility shift assays
For electrophoretic mobility shift assays, the cells were untreated or treated with LY for 24 h. The NFkB-binding site (5 0 -AGTTGAGGGGACTTTCCCAGG-3 0 ) from the immunoglobulin gene promoter was used as a probe. Briefly, complementary oligonucleotides, endlabeled with polynucleotide kinase and [g-32 P]ATP, were annealed by slow cooling. Approximately 20 000 cpm of probe was used per reaction mixture. Nuclear and cytoplasmic extracts were prepared in binding reaction buffer as described previously (Beg et al., 1993) . The binding reaction was carried out with nuclear extracts containing equal amounts of protein at room temperature for 30 min in a total volume of 20 ml. The DNA Á NFkB complexes were separated on 5% polyacrylamide gels by electrophoresis in low ionic strength Tris borate/ EDTA buffer. The gels were dried, and the labeled complexes were visualized by autoradiography.
Inducible cell lines
RKO colorectal cancer cell lines in which kinase-dead (KD) IkB Kinase a (IKKa) and wild type (WT) PTEN are inducible were established. To accomplish this, the RKO colorectal cancer cell line was transfected with pRXR (which codes for the ecdysone receptor and zeocin resistance) and the ecdysoneresponsive pIND plasmid from Invitrogen encoding for hygromycin resistance and either flag-tagged KD IKKa or GFP-tagged WT PTEN. Cells were selected in zeocin and hygromycin and clones were screened by Western blot analysis with antibodies against the appropriate epitope tag for protein induction in the presence of the synthetic ecdysone analog PN. In clone KDA, KD-IKKa is induced 24 h following addition of 1 mg/ml PN. In clone WPT, PTEN is induced 24 h following addition of 1 mg/ml PN.
Northern analysis and cancer profiling arrays
Cells were treated as indicated. Total RNA was isolated by using the TRIzol reagent from Invitrogen. RNA was fractionated by electrophoresis on a formaldehyde gel and transferred to Hybond-N according to the procedures provided by Amersham Biosciences (Piscataway, NJ, USA). cDNA probes for IL-8, uPA, EGF, VEGF-C, TGFa, COX2, MMP9, and GAPDH mRNAs were made using the random priming kit from Amersham Biosciences. Probe hybridization and washing were performed according to procedures provided by Amersham Biosciences and the signals were visualized by autoradiography. The cancer profiling array membrane from Clontech was hybridized with the cDNA probes for human IL-8, uPA, VEGF-C, and Ubiquitin according to the manufacturer's instructions. For consecutive hybridizations, filters were stripped in boiling 0.5% SDS solution. The filters were exposed to autoradiography. Signal intensity was measured by exposing to phosphorimagining screens and quantification using ImageQuant software from Amersham Biosciences.
Angiogenesis gene profiling array
KDA and WPT cells were untreated or treated with PN for 24 h. Total RNA was isolated by using the TRIzol reagent from Invitrogen. cDNA probes labeled with [a- 32 P]dCTP were produced by reverse transcription of total RNA following the protocol from Promega (Madison, WI, USA). The labeled cDNA probes were hybridized to a membrane containing 96 specific cDNA fragments of human genes known to be involved in angiogenesis and metastasis (Human Angiogenesis Gene Array GE Array Q Series) from SuperArray Inc. (Bethesda, MD, USA) according to the manufacturer's instructions. Signal intensity was measured by exposing to phosphorimaging screens and quantification using ImageQuant software from Amersham Biosciences.
Real-Time semiquantitative PCR confirmation of selected genes
To validate a subset of genes with significant changes, realtime, reverse transcription-PCR was performed. KDA and WPT cells were untreated or treated with PN for 24 h. Total RNA was isolated by using the TRIzol reagent (Invitrogen). Approximately 1 mg of total RNA from each sample was reverse-transcribed as described by the manufacturer, using the iScriptt cDNA Synthesis Kit from Bio-Rad (Hercules, CA, USA). Gene sequences available from the National Center for Biotechnology Information GenBank and Unigene databases were selected to design primers. Optimum primer sequences were selected after verification for gene-specific complementation using the National Center for Biotechnology Information Blast program. Semiquantitative analysis of gene expression was performed using the Bio-Rad iCycler IQ system using the manufacturer's protocol for the iQ SYBR Green Supermix kit supplied by Bio-Rad. cDNA concentrations for each sample were normalized by using two control genes that showed no change in expression on the arrays: b-actin and ubiquitin. Standard curves were generated by preparing serial dilutions, and the relative level of expression of each of the verified genes was determined.
Abbreviations NF-kB, nuclear factor kappa B; PI3K, phosphatidylinositol 3 0 kinase; IKK, IkB kinase; CRC, colorectal cancer; KD, kinase dead; WT, wild type; APC, adenomatous polyposis coli; GSK3b, glycogen synthase kinase 3b; TNF, tumor necrosis factor; IkBs, inhibitors of NFkB; MEFs, mouse embryo fibroblasts; TCF, T-cell factor; LEF, lymphoid-enhancer factor; IL-1, interleukin-1; HA, hemagglutinin; GFP, green fluorescent protein; IkBaSR, IkBa super repressor; LY 294 002, LY; IL-8, interleukin-8; uPA, urokinase-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; TGFa, transforming growth factor-a; COX2, cyclooxygenase 2; MMP, matrix metalloproteinase; PN, ponasterone A; GAPDH, glyceraldehyde phosphodehydrogenase.
